WeVote
Log In

Bill

Bill

SD 532

An Act relative to patient access to biomarker testing to provide appropriate therapy

194th Legislature (2025-2026) Introduced by Mike Brady and 17 co-sponsors

Requires Massachusetts insurers to cover cancer biomarker testing without prior authorization delays to enable personalized therapy selection.

0
WeVote Research Nonpartisan
Bill Summary · SD 532

Legislative bill overview

SD 532 requires health insurance plans in Massachusetts to cover biomarker testing without prior authorization delays when ordered by a healthcare provider for patients with cancer or other serious conditions. The bill aims to ensure patients can access genetic and molecular testing that helps determine the most effective treatment options based on their tumor's specific characteristics.

Why is this important

Biomarker testing identifies specific mutations or proteins in cancer cells that predict which targeted therapies will work best, potentially improving treatment outcomes and reducing unnecessary chemotherapy. Delays in accessing this testing can postpone appropriate treatment, while coverage barriers may force patients to pay out-of-pocket for tests that directly inform life-saving medical decisions.

Potential points of contention

  • Cost implications: Insurers may resist expanded coverage without prior authorization, arguing it increases healthcare costs, though proponents counter that targeted therapies actually reduce waste from ineffective treatments
  • Medical necessity standards: Disagreement over which biomarker tests are clinically necessary versus exploratory, particularly for rarer cancers or emerging testing technologies
  • Prior authorization framework: Debate over whether eliminating prior authorization entirely is appropriate versus creating expedited review processes that balance access with cost oversight

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.